Want to see VCYT full AI Analyst Report?
VCYT Stock Chart & Stats
$56.61
-$1.27(-2.19%)
At close: 4:00 PM EDT
$56.61
-$1.27(-2.19%)
Day’s Range― - ―
52-Week Range$22.92 - $60.91
Previous Close$55.6
Volume589.88K
Average Volume (3M)1.26M
Market Cap
$4.52B
Enterprise Value$2.22K
Total Cash (Recent Filing)$439.06M
Total Debt (Recent Filing)$39.33M
Price to Earnings (P/E)51.1
Beta1.19
Next Earnings
Jul 30, 2026EPS Estimate
0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.11
Shares Outstanding79,792,650
10 Day Avg. Volume1,010,796
30 Day Avg. Volume1,260,045
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)2.53
Price to Sales (P/S)6.40
P/FCF Ratio26.13
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$59.00Price Target Upside4.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)1.81
Revenue Forecast (FY)$586.37M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVeracyte's very low leverage and large equity base provide durable financial flexibility, lowering interest expense and preserving capacity to fund launches, M&A, or unexpected costs. This capital structure supports multi-quarter investment without forcing dilutive financing and cushions trial or reimbursement setbacks.
Improving Cash GenerationSustained positive operating and free cash flow gives Veracyte the internal financing to invest in R&D, commercialization, and working capital. Strong cash conversion reduces reliance on external capital, supports margin durability, and provides a multi-month runway to execute launches and absorb seasonal PPC variability.
Commercial Momentum And Near-term CatalystsRobust Decipher growth and operational improvements in Afirma show durable physician adoption and revenue diversification. Near-term commercial launches (Prosigna LDT, TruMRD) expand the product portfolio, creating structural upside to volumes and payer coverage assuming evidence and rollout proceed as planned.
Bears Say
Revenue Growth DecelerationA slowdown to mid-single-digit TTM growth versus prior rapid expansion increases dependence on new-product launches and execution to restore higher growth. Slower top-line momentum can compress operating leverage potential and makes multi-quarter guidance execution more sensitive to commercialization timing.
Binary Clinical Readout RiskKey product and label prospects hinge on binary trial outcomes (OPTIMA, ENZIMET). Negative or delayed readouts could materially impair Prosigna commercialization, slow guideline inclusion and payer acceptance, and reduce the near-term revenue runway that management expects from these catalysts.
Guideline And Reimbursement Timing UncertaintyEven with positive clinical data, uncertain timing for guideline updates and payer decisions can delay broad adoption and payment rates. This structural timing risk can stretch realization of anticipated revenues, weaken near-term pricing power, and lengthen the payback period on commercialization investments.
Veracyte News
VCYT FAQ
What was Veracyte Inc’s price range in the past 12 months?
Veracyte Inc lowest stock price was $22.92 and its highest was $60.91 in the past 12 months.
What is Veracyte Inc’s market cap?
Veracyte Inc’s market cap is $4.52B.
When is Veracyte Inc’s upcoming earnings report date?
Veracyte Inc’s upcoming earnings report date is Jul 30, 2026 which is tomorrow.
How were Veracyte Inc’s earnings last quarter?
Veracyte Inc released its earnings results on May 05, 2026. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.334 by $0.186.
Is Veracyte Inc overvalued?
According to Wall Street analysts Veracyte Inc’s price is currently Undervalued.
Does Veracyte Inc pay dividends?
Veracyte Inc does not currently pay dividends.
What is Veracyte Inc’s EPS estimate?
Veracyte Inc’s EPS estimate is 0.43.
How many shares outstanding does Veracyte Inc have?
Veracyte Inc has 79,792,650 shares outstanding.
What happened to Veracyte Inc’s price movement after its last earnings report?
Veracyte Inc reported an EPS of $0.52 in its last earnings report, beating expectations of $0.334. Following the earnings report the stock price went up 24.932%.
Which hedge fund is a major shareholder of Veracyte Inc?
Currently, no hedge funds are holding shares in VCYT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Veracyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$59.00 (4.22% Upside)
$59.00 (4.22% Upside)
Blogger Sentiment
Neutral
VCYT Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 8.3%
Last 30 Days ▲ 8.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
139.97%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.20%
Trailing 12-Months
Company Description
Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
VCYT Company Deck
VCYT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial picture: double-digit revenue and volume growth, margin expansion, robust adjusted EBITDA (30.8%), strong cash generation, and multiple near-term product catalysts (Prosigna LDT and TruMRD). The company emphasized a deep clinical evidence base, sustained Decipher momentum, operational wins on Afirma (V2 workflow), and continued investment in R&D and commercialization. Key risks discussed were binary clinical readouts (OPTIMA/ENZIMET), exclusion of new-product revenue from guidance, PPC variability, seasonal sample quality impacts, and the need for guideline/reimbursement progress—factors that inject execution and timing uncertainty but do not currently outweigh the suite of positive financial and commercial indicators.View all VCYT earnings summariesVCYT Stock 12 Month Forecast
Average Price Target
$59.00
▲(4.22% Upside)
Technical Analysis
Travere Therapeutics
―
Celcuity
―
Immunovant
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Ownership Overview
1.79% Insiders
34.34% Mutual Funds
1.34% Other Institutional Investors
26.77% Public Companies and
Individual Investors